BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ActiveSight Signs Protein Crystallography Agreement With Novo Nordisk A/S (NVO)


1/23/2006 11:41:54 AM

SAN DIEGO, Jan. 23 /PRNewswire/ -- ActiveSight announced that it has signed an agreement with Novo Nordisk A/S to provide protein crystallography services. ActiveSight will co-crystallize Novo Nordisk proprietary molecules with proteins expressed by ActiveSight. Additional details of the agreement were not disclosed.

"We are very pleased to add a company of Novo Nordisk's stature to our growing customer base. We look forward to supplying their scientists with structural information to accelerate their discovery efforts," stated Ronald V. Swanson, Ph.D., Chief Scientific Officer for ActiveSight.

This is the first announced agreement of 2006 for the protein crystallography services provider, which was founded in 2003.

ABOUT ACTIVESIGHT

ActiveSight(TM), a division of Rigaku Americas Corporation, features a Portfolio of "ready to go" drug targets for co-crystallography. The Protein Portfolio includes the oncology targets Focal adhesion kinase (FAK), Hsp90 and Aurora-A kinase; nuclear hormone receptor targets PPAR-delta and FXR, implicated in obesity; PDE-4 for asthma and inflammation; the hypertension target Renin; the type-II diabetes target FBPase; and the anti-infective target bacterial DNA gyrase.

ActiveSight also offers full gene-to-structure protein crystallography services for client's targets, including X-ray data collection and fragment-based screening, featuring the Rigaku FR-E and ACTOR automation systems. For more information visit www.active-sight.com.

ActiveSight is a trademark of Rigaku.

ActiveSight

CONTACT: Joy Silen, Director of Business Development of ActiveSight,+1-858-455-6870, info@active-sight.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES